Table 3.
Clinico-pathological associations of PD-L1 protein expression in primary EOC and corresponding peritoneal metastasis.
| Total | Primary EOC | Peritoneal metastasis | |||||
|---|---|---|---|---|---|---|---|
| PD-L1 Positive | PD-L1 Negative | p value | PD-L1 Positive | PD-L1 Negative | p value | ||
| No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | |||
| No. of patients | 194 | 63 (32.5) | 131 (67.5) | 89 (45.9) | 105 (54.1) | ||
| Age (Yrs) | |||||||
| ≤ 50 | 84 (43.3) | 30 (35.7) | 54 (64.3) | 0.4004 | 40 (47.6) | 44 (52.4) | 0.6704 |
| > 50 | 110 (56.7) | 33 (30.0) | 77 (70.0) | 49 (44.6) | 61 (55.4) | ||
| Histology type | |||||||
| High-grade Serous | 125 (64.4) | 44 (35.2) | 81 (64.8) | 0.9134 | 65 (52.0) | 60 (48.0) | 0.1919 |
| Low-grade Serous | 36 (18.6) | 9 (25.0) | 27 (75.0) | 11 (30.6) | 25 (69.4) | ||
| Mucinous | 13 (6.7) | 4 (30.8) | 9 (69.2) | 4 (30.8) | 9 (69.2) | ||
| Endometrioid | 14 (7.2) | 4 (28.6) | 10 (71.4) | 6 (42.9) | 8 (57.1) | ||
| Clear cell | 3 (1.6) | 1 (33.3) | 2 (66.7) | 1 (33.3) | 2 (66.7) | ||
| Undifferentiated | 3 (1.6) | 1 (33.3) | 2 (66.7) | 2 (66.7) | 1 (33.3) | ||
| FIGO grade | |||||||
| Grade 1 | 27 (14.4) | 6 (22.2) | 21 (77.8) | 0.3354 | 7 (25.9) | 20 (74.1) | 0.0330 |
| Grade 2 | 66 (35.1) | 21 (31.8) | 45 (68.2) | 30 (45.5) | 36 (54.5) | ||
| Grade 3 | 95 (50.5) | 35 (36.8) | 60 (63.2) | 51 (53.7) | 44 (46.3) | ||
| pT | |||||||
| T1 | 7 (3.6) | 2 (28.6) | 5 (71.4) | 0.9731 | 2 (28.6) | 5 (71.4) | 0.5963 |
| T2 | 12 (6.2) | 4 (33.3) | 8 (66.7) | 5 (41.7) | 7 (58.3) | ||
| T3 | 175 (90.2) | 57 (32.6) | 118 (67.4) | 82 (46.9) | 93 (53.1) | ||
| pN | |||||||
| pN0 | 171 (88.1) | 50 (29.2) | 121 (70.8) | 0.0112 | 75 (43.9) | 96 (56.1) | 0.1245 |
| pN1 | 23 (11.9) | 13 (56.5) | 10 (43.5) | 14 (60.9) | 9 (39.1) | ||
| pM | |||||||
| pM0 | 153 (78.9) | 50 (32.7) | 103 (67.3) | 0.9059 | 72 (47.1) | 81 (52.9) | 0.5222 |
| pM1 | 41 (21.1) | 13 (31.7) | 28 (68.3) | 17 (41.5) | 24 (58.5) | ||
| Stage | |||||||
| I | 8 (4.1) | 4 (50.0) | 4 (50.0) | 0.7473 | 4 (50.0) | 4 (50.0) | 0.5408 |
| II | 8 (4.1) | 3 (37.5) | 5 (62.5) | 2 (25.0) | 6 (75.0) | ||
| III | 137 (70.6) | 43 (31.4) | 94 (68.6) | 66 (48.2) | 71 (51.8) | ||
| IV | 41 (21.2) | 13 (31.7) | 28 (68.3) | 17 (41.5) | 24 (58.5) | ||
| Residual tumor | |||||||
| Present | 75 (38.7) | 29 (38.7) | 46 (61.3) | 0.1455 | 35 (46.7) | 40 (53.3) | 0.8608 |
| Absent | 119 (61.3) | 34 (28.6) | 85 (71.4) | 54 (45.4) | 65 (54.6) | ||
| MMR IHC | |||||||
| pMMR | 185 (98.4) | 63 (34.1) | 105 (65.9) | 0.1158 | 87 (47.0) | 98 (53.0) | 0.6332 |
| dMMR | 3 (1.6) | 0 (0.0) | 3 (100.0) | 1 (33.3) | 2 (66.7) | ||
| Ki-67 IHC | |||||||
| High | 111 (59.0) | 40 (36.0) | 71 (64.0) | 0.3769 | 61 (54.9) | 50 (45.1) | 0.0039 |
| Low | 77 (41.0) | 23 (29.9) | 54 (70.1) | 26 (33.8) | 51 (66.2) | ||
| Progression-free survival | |||||||
| Median (months) | 14.0 | 13.0 | 0.7240 | 14.0 | 12.0 | 0.5245 | |
| Range (months) | 2.0–87.0 | 2.0–93.0 | 3.0–93.0 | 2.0–92.0 | |||
| Median absolute deviation (months) | 6.0 | 7.0 | 7.0 | 5.0 | |||
MMR mismatch repair, pMMR proficient MMR, dMMR deficient MMR.